BR112019008762A2 - método para o tratamento de um distúrbio proliferativo mutado em flt3 - Google Patents

método para o tratamento de um distúrbio proliferativo mutado em flt3

Info

Publication number
BR112019008762A2
BR112019008762A2 BR112019008762A BR112019008762A BR112019008762A2 BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2 BR 112019008762 A BR112019008762 A BR 112019008762A BR 112019008762 A BR112019008762 A BR 112019008762A BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2
Authority
BR
Brazil
Prior art keywords
patient
crenolanib
flt3
treating
genetic abnormalities
Prior art date
Application number
BR112019008762A
Other languages
English (en)
Inventor
Vinay K Jain
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019008762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of BR112019008762A2 publication Critical patent/BR112019008762A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

crenolanibe para tratar doenças proliferativas com mutação de flt3 associadas às mutações a presente invenção inclui os métodos para tratar uma doença proliferativa com mutação de flt3 compreendendo: medir a expressão de um flt3 com mutação e um ou mais anormalidades genéticas em uma amostra obtida de uma amostra de tumor obtida do paciente, em que a presença de uma ou mais anormalidades genéticas indica que o paciente tem um prognóstico deficiente; e administrar ao paciente uma quantidade terapeuticamente efetiva de crenolanibe ou seu sal farmaceuticamente aceitável, em que o crenolanibe aumenta uma chance de sobrevivência do paciente tanto com o flt3 com mutação e uma ou mais anormalidades genéticas, em que o crenolanibe, conforme abaixo mostrado, é administrado a uma pessoa sofrendo da referida doença.
BR112019008762A 2016-11-02 2017-10-31 método para o tratamento de um distúrbio proliferativo mutado em flt3 BR112019008762A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
PCT/US2017/059377 WO2018085292A1 (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations

Publications (1)

Publication Number Publication Date
BR112019008762A2 true BR112019008762A2 (pt) 2019-07-16

Family

ID=62020370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008762A BR112019008762A2 (pt) 2016-11-02 2017-10-31 método para o tratamento de um distúrbio proliferativo mutado em flt3

Country Status (19)

Country Link
US (2) US11078541B2 (pt)
EP (1) EP3359155A4 (pt)
JP (2) JP2019532011A (pt)
KR (2) KR20180074792A (pt)
CN (1) CN108778276A (pt)
AU (1) AU2017353925A1 (pt)
BR (1) BR112019008762A2 (pt)
CA (1) CA3024012A1 (pt)
CL (1) CL2019001208A1 (pt)
CO (1) CO2019005466A2 (pt)
EA (1) EA201991078A1 (pt)
HK (1) HK1257195A1 (pt)
IL (1) IL266303A (pt)
MX (1) MX2019005008A (pt)
PE (1) PE20191238A1 (pt)
PH (1) PH12019500965A1 (pt)
SG (1) SG11201903889TA (pt)
WO (1) WO2018085292A1 (pt)
ZA (1) ZA201903089B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191238A1 (es) * 2016-11-02 2019-09-11 Arog Pharmaceuticals Inc Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (zh) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 一种hyml-122血药浓度定量分析方法
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (zh) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ES2247187T3 (es) 2000-10-17 2006-03-01 MERCK & CO., INC. Sales oralmente activas conactividad tirosina quinasa.
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PL211461B1 (pl) 2001-10-30 2012-05-31 Dana Farber Cancer Inst Inc Zastosowanie pochodnych staurosporyny do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania białaczkom i zespołom mielodysplastycznym, preparat farmaceutyczny do leczenia białaczek i zestaw farmaceutyczny
CA2470480C (en) 2001-12-27 2010-12-14 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
KR20110108404A (ko) 2002-11-13 2011-10-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암을 치료하는 방법 및 관련 방법
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
KR100787649B1 (ko) 2003-06-24 2007-12-21 화이자 프로덕츠 인크. 1-[(벤조이미다졸-1-일)퀴놀린-8-일]피페리딘-4-일아민유도체의 제조 방법
EP2417267B1 (en) * 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
WO2013138237A1 (en) * 2012-03-12 2013-09-19 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
PE20191238A1 (es) * 2016-11-02 2019-09-11 Arog Pharmaceuticals Inc Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado

Also Published As

Publication number Publication date
PH12019500965A1 (en) 2019-12-02
CL2019001208A1 (es) 2019-07-26
US11078541B2 (en) 2021-08-03
JP2022071099A (ja) 2022-05-13
WO2018085292A1 (en) 2018-05-11
EA201991078A1 (ru) 2019-11-29
US20180117031A1 (en) 2018-05-03
CA3024012A1 (en) 2018-05-11
EP3359155A4 (en) 2019-05-22
SG11201903889TA (en) 2019-05-30
PE20191238A1 (es) 2019-09-11
KR20200079351A (ko) 2020-07-02
JP2019532011A (ja) 2019-11-07
EP3359155A1 (en) 2018-08-15
CN108778276A (zh) 2018-11-09
US20210324481A1 (en) 2021-10-21
KR20180074792A (ko) 2018-07-03
ZA201903089B (en) 2019-12-18
AU2017353925A1 (en) 2018-09-27
IL266303A (en) 2019-06-30
HK1257195A1 (zh) 2019-10-18
MX2019005008A (es) 2019-09-10
CO2019005466A2 (es) 2019-07-31

Similar Documents

Publication Publication Date Title
BR112019008762A2 (pt) método para o tratamento de um distúrbio proliferativo mutado em flt3
Wang et al. Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats
BR112017023233A2 (pt) métodos para tratamento de câncer
BR112015016282A2 (pt) crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
Tao et al. DHEA attenuates microglial activation via induction of JMJD3 in experimental subarachnoid haemorrhage
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112016000177A2 (pt) usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
BR112014029338A2 (pt) biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
BR112018012626A2 (pt) ccl20 como um preditor de resposta clínica a antagonistas de il23
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
JP2016519107A5 (pt)
BR112015029709A2 (pt) dihidroetorfina para o fornecimento de alívio da dor e anestesia
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
Jimenez et al. A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheo-chromocytomas and paragangliomas
BR112019007028A2 (pt) métodos e composições farmacêuticas para o tratamento do câncer renal
MX2016005858A (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales.
BR112016024502A8 (pt) uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento
Poverennova et al. Diagnosis and treatment of asthenic syndrome in elderly people after acute respiratory viral infection
MX2020003682A (es) Metodos para tratar enfermedades asociadas con ciliopatias.
Lyashenko et al. Melatonin in correction of REM-sleep behavior disorders in Parkinson's disease
BR112016011811A2 (pt) Uso de um inibidor de fosfatidilinositol 3-cinase seletivo de alfa-isoforma, regime terapêutico e pacote

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements